What Matters Now
CME
Making Treatment Decisions in Early Alzheimer’s Disease: Biomarkers, ARIA, and When to Start Therapy
Pierre Tariot, MD, Banner Alzheimer’s Institute
Dani Cabral, MD, BrainLove
87% of Peers Changed Their Practice After this Clinical Scenario
CME
Determining whether to initiate time-sensitive anti-amyloid therapy despite unresolved patient preference, limited caregiver availability, and absent MRI/ARIA workflows.
What Matters Now
CME
Making Treatment Decisions in Early Alzheimer’s Disease:
Biomarkers, ARIA, and When to Start Therapy
Pierre Tariot, MD, Banner Alzheimer’s Institute
Dani Cabral, MD, BrainLove
Corresponding Scenario
The Diagnosis Is Confirmed - But Is This Patient Ready to Start?
See experiences from 195 peers
Determining whether to initiate time-sensitive anti-amyloid therapy despite unresolved patient preference, limited caregiver availability, and absent MRI/ARIA workflows.
How clinicians responded after this Clinical Scenario
67
%
begin unsure how to apply evidence
87
%
will implement a practice change
